Acute Myeloid Leukemia News and Research

RSS

Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

New $2.3 million NCI grant awarded to Georgia Cancer Center to improve survival of patients with AML

Acute myeloid leukemia (AML) is a cancer that affects blood cells in the bone marrow -; the spongy tissue inside certain bones, where new blood cells are made.

17 Apr 2023

St. Jude computational biologists characterize the full spectrum of oncogenic fusions in pediatric cancer

The scientific foundation needed to work on curing a class of cancer-causing mutations is here, in the form of a tool from St. Jude Children's Research Hospital.

5 Apr 2023

New research may upend long-held scientific dogma about short telomeres and cancer risk

Johns Hopkins Medicine scientists say their 20-year study of more than 200 people with premature aging syndromes caused by abnormally short telomeres, or shortened repetitive DNA sequences at the ends of chromosomes, may upend long-held scientific dogma and settle conflicting studies about how and whether short telomeres contribute to cancer risk.

30 Mar 2023

Scientists develop a marker for therapy response in acute myeloid leukemia

With the combination of the drugs Venetoclax and 5-Azacitidine, a new, effective and more tolerable alternative to chemotherapy for the treatment of AML has been available for several years. But for some patients, the drug combination does not work.

17 Mar 2023

AI-assisted analysis helps find new targets for CAR-T cell therapy against acute myeloid leukemia

Unlike other forms of blood cancer, acute myeloid leukemia (AML) cannot currently be treated with CAR-T cell immunotherapy.

13 Mar 2023

Montana considers new wave of legislation to loosen vaccination rules

When Deb Horning's youngest daughter was 5, she got her measles, mumps, and rubella shot like many other kindergartners. But unlike many other moms, Horning had to stay away from her daughter for a week after the shot.

10 Mar 2023

Detection and targeting of splicing deregulation reveal a potential strategy for pAML therapy

Pediatric acute myeloid leukemia or pAML is a childhood blood cancer, one that has proved confounding to clinicians and researchers, with a high relapse rate and relatively few identified genetic mutations (compared to the adult version) that might explain its cause.

8 Mar 2023

Study identifies a potential new treatment approach for acute myeloid leukemia

A team of researchers has discovered a potential therapeutic that can synergize with existing drugs to more effectively kill certain leukemia cells.

8 Mar 2023

Research shows the benefits of screening AML patients in remission for residual disease before bone marrow transplant

Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from acute myeloid leukemia (AML) for residual disease before receiving a bone marrow transplant.

7 Mar 2023

Study identifies a potential new targeted drug for treating acute myeloid leukemia

Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone.

23 Feb 2023

Fetal cell program appears to protect against acute myeloid leukemia

During the fetal stage, a number of so-called cell programs run that are vital to the development of the fetus.

21 Feb 2023

Small molecule inhibitor reverses malignant hyper-editing by an inflammation-induced protein isoform

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

16 Feb 2023

Novel type of combination therapy shows potential in acute myeloid leukemia

Acute myeloid leukemia (AML) is an aggressive form of cancer that originates in the bone marrow, rapidly spreads to the blood and can quickly cause death if not treated promptly.

7 Feb 2023

Integrated NGS system can deliver accurate, genomics-based diagnoses to accelerate treatment for myeloid neoplasms

Identifying recurrent genetic alterations in myeloid neoplasms has improved diagnosis and expanded targeted treatments available to patients. However, treatment initiation can be delayed by the variable and lengthy turnaround times involved in testing for these alterations.

7 Feb 2023

What is the effectiveness of different exercise modalities in reducing cancer-related fatigue in cancer patients undergoing chemotherapy?

Researchers examined the effect of exercise modalities on cancer-related fatigue.

6 Feb 2023

Characterization of Ikaros zinc finger protein 1 mutations in acute myeloid leukemia

Researchers evaluated the clinical and genetic characteristics of acute myeloid leukemia (AML) patients with a mutant Ikaros zinc finger protein 1 (IKZF1).

2 Feb 2023

Scientists illuminate how blood cancer treatments can lead to therapy-related myeloid neoplasms

Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have illuminated how treatments for multiple myeloma and other aggressive blood cancers can lead to future malignancies, called therapy-related myeloid neoplasms (tMNs).

25 Jan 2023

Acute Myeloid Leukemia News and Research

Further Reading